CDNA
CareDx, Inc · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -5.9% ·
share flow -2.6% ·
net new positions -6.2%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 7.59K | $472,199 | n/a | n/a |
| Q2 2026 | 93 | +15 | 33.33M | $949.30M | +15 | −2 |
| Q1 2026 | 83 | +3 | 34.73M | $602.98M | +6 | −3 |
| Q4 2025 | 80 | +2 | 35.05M | $660.43M | +2 | n/a |
| Q3 2025 | 16 | -1 | 19.38M | $281.84M | n/a | −1 |
| Q2 2025 | 14 | -2 | 18.42M | $359.99M | n/a | −2 |
| Q1 2025 | 13 | -1 | 10.08M | $178.96M | n/a | −1 |
| Q4 2024 | 14 | 0 | 12.01M | $257.21M | +1 | −1 |
| Q3 2024 | 13 | +2 | 9.17M | $286.29M | +2 | n/a |
| Q2 2024 | 11 | n/a | 12.97M | $201.49M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 4.77M | +2.3% | $69.31M | 0.0% | ▲ Add | 2 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (passive) | 3.75M | -23.6% | $54.52M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 2.57M | +17.7% | $37.32M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | ARK Investment Management ✦ | 2.17M | +3.4% | $31.56M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.30M | -2.0% | $18.87M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | Renaissance Technologies ✦ | 1.16M | 0.0% | $16.80M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 862.28K | n/a | $12.54M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Citadel Advisors ✦ | 623.81K | -21.1% | $9.07M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | D. E. Shaw & Co. ✦ | 594.49K | -3.4% | $8.64M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 10 | Morgan Stanley ✦ | 486.30K | n/a | $7.07M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 11 | Millennium Management ✦ | 413.69K | +504.0% | $6.02M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 187.91K | -27.7% | $2.73M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 13 | Wellington Management ✦ | 184.62K | +11.5% | $2.68M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 14 | Fidelity (FMR) ✦ | 155.62K | +3595.5% | $2.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | JPMorgan Chase ✦ | 129.32K | n/a | $1.88M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 16 | T. Rowe Price ✦ | 38.51K | +11.5% | $560,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $3.06M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 189 holders, 52.20M shares, $899.83M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.